



## Novel conduction-repolarization indices for the stratification of arrhythmic risk

Gary Tse

Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. E-mail: gary.tse@doctors.org.uk

*J Geriatr Cardiol* 2016; 13: 811–812. doi:10.11909/j.issn.1671-5411.2016.09.008

**Keywords:** Conduction; Depolarization; QRS; QT dispersion; Repolarization; Transmural dispersion of repolarization; Wavelength

Sudden cardiac death (SCD) affects approximately 800,000 individuals per annum globally.<sup>[1]</sup> It is most frequently due to cardiac tachy-arrhythmias, which include mono-morphic or polymorphic ventricular tachycardia (VT), torsade de pointes and ventricular fibrillation (VF). Risk stratification for SCD remains a challenging problem in clinical practice. Patients with structural heart disease or cardiac ion channelopathies have an increased risk of SCD, their risks are not the same. Consequently, several indices have been devised for this purpose, mainly focusing on ventricular repolarization, which is reflected by the QT interval on the electrocardiogram.<sup>[2]</sup> These include QT interval corrected for heart rate ( $QT_c$ ), QT dispersion ( $QT_d$ ), interval from the peak to the end of the T wave ( $T_{peak} - T_{end}$ , reflecting increased transmural dispersion of repolarization, TDR), and  $(T_{peak} - T_{end})/QT$  ratio.<sup>[3]</sup>

There are two major problems with these indices. Firstly, TDR has been shown to be a poor predictor of arrhythmogenicity in pre-clinical models even in disorders of repolarization, such as long QT and short QT syndromes. Secondly, none of the above indices takes into account the role of abnormal conduction in ventricular arrhythmogenesis. It may be reasonable to assume that abnormal conduction plays a minor role in disorders primarily affecting repolarization. However, it is not appropriate to do so in structural heart diseases such as heart failure or Brugada syndrome. In these conditions, reduced conduction velocities (CVs) are observed,<sup>[4]</sup> which manifest as prolonged QRS durations on the ECG.<sup>[5,6]</sup> Reduced CV increases the risk of reentrant arrhythmias by shortening the excitation wavelength  $\lambda$  given by  $CV \times$  effective refractory period, as demonstrated in pre-clinical experiments. However, a major disadvantage of  $\lambda$  is that it must be determined invasively by electrophysiological studies in humans.

In view of this, there is a need for arrhythmic risk markers that take into account both conduction and repolarization.

Recently, the index of Cardiac Electrophysiological Balance, iCEB, given by  $QT/QRS$ , was proposed.<sup>[7]</sup> This ratio can easily be derived from the electrocardiogram and is a good approximate of  $\lambda$ .

Previous work has shown that  $T_{peak} - T_{end}$  and  $(T_{peak} - T_{end})/QT$  are superior to the QT interval in predicting arrhythmic risk.<sup>[2]</sup> Thus, I recently proposed two novel indices,  $(T_{peak} - T_{end})/QRS$  and  $(T_{peak} - T_{end})/(QT \times QRS)$ , that might be able to better predict arrhythmic risk in Brugada syndrome.<sup>[8,9]</sup> There is no reason why these cannot not be applied in other clinical conditions where conduction is abnormal, such as heart failure. The advantage of  $(T_{peak} - T_{end})/QRS$  is that it can be easily calculated and therefore sufficiently convenient for clinical use.  $(T_{peak} - T_{end})/(QT \times QRS)$  is potentially more accurate for risk stratification for research purposes, but is too cumbersome to use by the bedside. Both indices are derived from electrophysiological findings that both conduction and repolarization abnormalities are important in arrhythmogenesis. The validity of these indices will require further study, but may ultimately provide superior predictive values than ventricular repolarization markers such as  $QT_c$ ,  $QT_d$ ,  $T_{peak} - T_{end}$  or  $(T_{peak} - T_{end})/QT$  ratio. Animal models are useful for studying arrhythmogenic mechanisms and provide a platform for assessing the efficacy of pharmacological therapy.<sup>[10–16]</sup> Measurement of the magnetic field in the heart has been useful for characterizing cardiac structural abnormalities.<sup>[17–19]</sup> It can be used to diagnose and predict the risk of cardiac arrhythmias in clinical practice by magnetocardiography, which may provide helpful clinical markers for risk stratification in the future.<sup>[20]</sup>

### Acknowledgements

The author would like to thank Croucher Foundation of Hong Kong for the support of his clinical assistant professorship.

## References

- 1 Choy L, Yeo JM, Tse V, *et al.* Cardiac disease and arrhythmogenesis: mechanistic insights from mouse models. *Int J Cardiol Heart Vasc* 2016; 12: 1–10.
- 2 Castro-Torres Y, Carmona-Puerta R, Katholi RE. Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. *World J Clin Cases* 2015; 3: 705–720.
- 3 Tse G, Yan BP. Traditional and novel electrocardiographic conduction and repolarization markers of sudden cardiac death. *Europace*. Published Online First: 2016. Doi: 10.1093/europace/euw280.
- 4 Tse G, Wong ST, Tse V, Yeo JM. Depolarization vs. repolarization: what is the mechanism of ventricular arrhythmogenesis underlying sodium channel haploinsufficiency in mouse hearts? *Acta Physiol (Oxf)*. Published Online First: 16 Apr 2016. Doi: 10.1111/apha.12694.
- 5 Ohkubo K, Watanabe I, Okumura Y, *et al.* Prolonged QRS duration in lead V2 and risk of life-threatening ventricular Arrhythmia in patients with Brugada syndrome. *Int Heart J* 2011; 52: 98–102.
- 6 Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. *J Am Coll Cardiol* 2005; 46: 2183–2192.
- 7 Lu HR, Yan G-X, Gallacher DJ. A new biomarker – index of Cardiac Electrophysiological Balance (iCEB) – plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). *J Pharmacol Toxicol Methods* 2013; 68: 250–259.
- 8 Tse G. (Tpeak-Tend)/QRS and (Tpeak-Tend)/(QT x QRS): novel markers for predicting arrhythmic risk in the Brugada syndrome. *Europace*. Published Online First: 2016. Doi: 10.1093/europace/euw194.
- 9 Tse G, Yan BP. Novel arrhythmic risk markers incorporating QRS dispersion:  $QRSd \times (T_{peak} - T_{end}) / QRS$  and  $QRSd \times (T_{peak} - T_{end}) / (QT \times QRS)$ . *Ann Noninvasive Electrocardiol*. Published Online First: 18 Aug 2016. Doi: 10.1111/anec.12397.
- 10 Tse G, Lai ET, Yeo JM, Y, *et al.* Electrophysiological mechanisms of Bayés syndrome: insights from clinical and mouse studies. *Front Physiol* 2016; 7: 188.
- 11 Tse G, Lai ET, Chan YW, *et al.* What is the arrhythmic substrate in viral myocarditis? Insights from clinical and animal studies. *Front Physiol* 2016; 7: 308.
- 12 Tse G, Yan BP, Chan YW, *et al.* Reactive oxygen species, endoplasmic reticulum stress and mitochondrial dysfunction: the link with cardiac arrhythmogenesis. *Front Physiol* 2016; 7: 313.
- 13 Tse G, Lai TH, Yeo JM, *et al.* Mechanisms of electrical activation and conduction in the gastrointestinal system: lessons from cardiac electrophysiology. *Front Physiol* 2016; 7: 182.
- 14 Tse G, Lai ET, Lee AP, *et al.* Electrophysiological mechanisms of gastrointestinal arrhythmogenesis: lessons from the heart. *Front Physiol* 2016; 7: 230.
- 15 Tse G, Lai ET, Tse V, *et al.* Molecular and electrophysiological mechanisms underlying cardiac arrhythmogenesis in diabetes mellitus. *J Diabetes Res*. Published Online First: 2016. <http://dx.doi.org/10.1155/2016/2848759>.
- 16 Chen Z, Sun B, Tse G, *et al.* Reversibility of both sinus node dysfunction and reduced HCN4 mRNA expression level in an atrial tachycardia pacing model of tachycardia-bradycardia syndrome in rabbit hearts. *Int J Clin Exp Pathol* 2016; 9: 8526–8531.
- 17 Tse G, Ali A, Alpendurada F, *et al.* Tuberculous constrictive pericarditis. *Res Cardiovasc Med* 2015; 4: e29614.
- 18 Tse G, Ali A, Prasad SK, *et al.* Atypical case of post-partum cardiomyopathy: an overlap syndrome with arrhythmogenic right ventricular cardiomyopathy? *BJR Case Rep* 2015; 1: 201500182.
- 19 Vassiliou V, Chin C, Perperoglou A, *et al.* Ejection fraction by cardiovascular magnetic resonance predicts adverse outcomes post aortic valve replacement. *Heart* 2014; 100 (Suppl 1 3): A53–A54.
- 20 Ito Y, Shiga K, Yoshida K, *et al.* Development of a magneto-cardiography-based algorithm for discrimination between ventricular arrhythmias originating from the right ventricular outflow tract and those originating from the aortic sinus cusp: a pilot study. *Heart Rhythm* 2014; 11: 1605–1612.